These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1451643)

  • 1. Microbiologic profile of ceftibuten, a new oral cephalosporin.
    Debbia EA; Pesce A; Chiesa M; Ricotta N; Schito GC
    Drugs Exp Clin Res; 1992; 18(4):129-39. PubMed ID: 1451643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of ceftibuten, a new oral third generation cephalosporin.
    Debbia EA; Schito GC; Pesce A
    J Chemother; 1991 Aug; 3(4):209-25. PubMed ID: 1779255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.
    Jones RN
    Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S77-83. PubMed ID: 7567314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A comparative study of antibacterial activity of ceftibuten, ceftazidime, cefuroxime and ampicillin against clinical isolates].
    Ergova R; K'oleian E; Kharalambieva Ia; Mitov I; Docheva Iu
    Vutr Boles; 2000; 32(1):13-7. PubMed ID: 11195191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity and spectrum of ceftibuten (7432-S, SCH 39720)--a review of United States and Canadian results.
    Jones RN
    Diagn Microbiol Infect Dis; 1991; 14(1):37-43. PubMed ID: 2013209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftibuten: minimal inhibitory concentrations, postantibiotic effect and beta-lactamase stability--a rationale for dosing programs.
    Neu HC
    Pediatr Infect Dis J; 1995 Jul; 14(7 Suppl):S88-92. PubMed ID: 7567316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
    Mushtaq S; Warner M; Ge Y; Kaniga K; Livermore DM
    J Antimicrob Chemother; 2007 Aug; 60(2):300-11. PubMed ID: 17548456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of FCE 22101 against respiratory tract pathogens with reference to production of beta-lactamases.
    Dornbusch K; Kronvall G; Göransson E; Mörtsell E
    J Antimicrob Chemother; 1989 Mar; 23 Suppl C():31-41. PubMed ID: 2786517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial effects of the combination of ceftibuten and an orally absorbed penem SCH 29482.
    Chin NX; Gu JW; Neu HC
    Diagn Microbiol Infect Dis; 1991; 14(1):79-83. PubMed ID: 2013213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative antibacterial activity of ceftibuten (SH 39 720) against 150 K. pneumoniae strains producing different beta-lactamases].
    Thabaut A; Meyran M
    Pathol Biol (Paris); 1990 May; 38(5):347-51. PubMed ID: 2195446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftibuten and bactericidal kinetics. Comparative in vitro activity against Enterobacteriaceae producing extended spectrum beta-lactamases.
    Bauernfeind A
    Diagn Microbiol Infect Dis; 1991; 14(1):89-92. PubMed ID: 2013215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftibuten pharmacokinetics and pharmacodynamics. Focus on paediatric use.
    Kearns GL; Young RA
    Clin Pharmacokinet; 1994 Mar; 26(3):169-89. PubMed ID: 8194281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftibuten: a new orally absorbed cephalosporin. In vitro activity against strains from the United Kingdom.
    Wise R; Andrews JM; Ashby JP; Thornber D
    Diagn Microbiol Infect Dis; 1991; 14(1):45-52. PubMed ID: 2013210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of oral cephalosporin BAY v 3522 compared with other oral cephalosporins.
    Locher R; Strässle A; Kayser FH
    Drugs Exp Clin Res; 1990; 16(10):515-25. PubMed ID: 2100734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro studies with Bay V 3522, a new oral cephalosporin.
    Thomson KS; Sanders CC; Sanders WE
    Drugs Exp Clin Res; 1991; 17(3):165-73. PubMed ID: 1914843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefdinir: in vitro activity study and effect of human serum.
    García-Rodríguez JA; Trujillano-Martín I; García-Sánchez JE
    Drugs Exp Clin Res; 1993; 19(2):51-8. PubMed ID: 8223142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro characterization of cefditoren, a new oral cephalosporin.
    Felmingham D; Robbins MJ; Ghosh G; Bhogal H; Mehta MD; Leakey A; Clark S; Dencer CA; Ridgway GL; Grüneberg RN
    Drugs Exp Clin Res; 1994; 20(4):127-47. PubMed ID: 7813385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.
    Deshpande L; Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2004 Sep; 50(1):73-5. PubMed ID: 15380281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of ceftibuten at sub-inhibitory concentrations in comparison with other antibiotics against respiratory and urinary tract pathogens.
    Maioli E; Marchese A; Roveta S; Cagnacci S; Cavallini F; Cassanelli C; Gualco L; Debbia EA
    J Chemother; 2007 Apr; 19(2):152-60. PubMed ID: 17434823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.